1.
FEMS Immunol Med Microbiol
; 46(3): 386-92, 2006 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16553812
RESUMO
This study reports the preliminary assessment of the safety and immunogenicity of the first serogroup C conjugate vaccine candidate that includes meningococcal P64k recombinant protein as the carrier (MenC/P64k). Twenty volunteers were recruited for a double-blind, randomized, controlled phase I clinical trial, receiving a single dose of MenC/P64k (study group) and a single dose of the commercial polysaccharide vaccine AC (control group). Only mild reactions were observed. No statistical differences were detected between the antipolysaccharide C IgG responses of both groups as well as between bactericidal serum titre (P > 0.05). The MenC/P64k vaccine was found to have a good safety profile, to be well tolerated and immunogenic.
Assuntos
Proteínas da Membrana Bacteriana Externa/imunologia , Infecções Meningocócicas/imunologia , Vacinas Meningocócicas/efeitos adversos , Vacinas Meningocócicas/imunologia , Neisseria meningitidis Sorogrupo C/imunologia , Adulto , Anticorpos Antibacterianos/sangue , Testes de Fixação de Complemento , Cuba , Método Duplo-Cego , Ensaio de Imunoadsorção Enzimática , Humanos , Masculino , Infecções Meningocócicas/prevenção & controle , Vacinas Conjugadas/efeitos adversos , Vacinas Conjugadas/imunologia
2.
Enferm Infecc Microbiol Clin
; 23(9): 573-4, 2005 Nov.
Artigo
em Espanhol
| MEDLINE
| ID: mdl-16324572